Investment Summary

Eight Roads Invests In Shadowfax Technologies

On September 11, 2015, private equity firm Eight Roads invested in transportation company Shadowfax Technologies

Investment Highlights
  • This is Eight Roads’ 1st transaction in the Transportation sector.
  • This is Eight Roads’ 18th transaction in India.

Investment Summary
Date 2015-09-11
Target Shadowfax Technologies
Sector Transportation
Investor(s) Eight Roads
Deal Type Venture

Target

Shadowfax Technologies

Bengaluru, India
Shadowfax Technologies is a hyperlocal logistics service provider that takes care of delivery requirements of local businesses. Shadowfax Technologies was founded in 2015 and is based in Bengaluru, India.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Eight Roads

Investor

Category Private Equity Firm
Founded 1969
Size Small
Type Sector Focused
DESCRIPTION

Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.

DEAL STATS #
Overall 111 of 298
Sector (Transportation) 1 of 2
Type (Venture) 93 of 269
Country (India) 18 of 38
Year (2015) 23 of 26
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-09-11 CredR

Bengaluru, India

CredR is an online platform for buying and selling pre-owned bikes in India. CredR is based in Bengaluru, India.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-09-16 Regenxbio

Rockville, Maryland, United States

Regenxbio is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Regenxbio’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. Regenxbio and its third-party NAV Technology licensees are applying the NAV Technology Platform in the development of a broad pipeline of product candidates in multiple therapeutic areas. Regenxbio was founded in 2008 and is based in Rockville, Maryland.

Sell -
Mergr

Product

Company

Legal